UTC CAR-T Phase 1 Trial (NCT06256055)

Life expectancy after CAR T-cell therapy varies by cancer type and response. For relapsed or refractory large B-cell lymphoma, studies report a 5-year overall survival rate of 32% across 115 infused participants, rising to 56% among responders, with CAR T-cells detectable beyond 5 years in some. In chronic lymphocytic leukemia, 77% of 31 patients progression-free at 1 year remained so at median 6.5-year follow-up, including 79% with over 5 years. Across large B-cell lymphomas, median overall survival reached 21 months at 12.4-month median follow-up, with 12-month rates at 59.4%; nonrelapse mortality was 5%, mainly from late infections. In B-cell non-Hodgkin lymphoma, 10-year overall survival was 58.1% at 10.2-year median follow-up.

No cure exists for mesothelioma as of 2026. Approved first-line treatments include nivolumab plus ipilimumab immunotherapy (FDA-approved, with 3-year PFS of 14% vs. 1% for chemotherapy) and pembrolizumab plus chemotherapy (ORR 22% vs. 6%). Over 80 active clinical trials test emerging therapies like enzyme therapy (ADI-PEG20 extended survival 4-fold at 3 years), cancer vaccines (UV1 doubled response rates), and targeted therapies, with median survival reaching 18+ months in some multimodal approaches. Research shows improved outcomes but no evidence of curative potential yet.

Many private health insurance plans cover CAR T-cell therapy for FDA-approved indications, though coverage varies by plan, with some limiting payments or denying claims labeled as experimental or not medically necessary. Medicare covers autologous CAR T-cell therapy at FDA REMS-enrolled facilities for medically accepted indications, including FDA-approved uses or those supported by CMS-approved compendia, while Medicaid covers it in certain states. People with mesothelioma or other cancers may face out-of-pocket costs like deductibles, and denials can be appealed internally or externally with medical documentation. Costs range from $500,000 to $1 million, prompting some insurers to deny despite 76% remission rates in treated cases. Treatment centers often assist with prior authorization and benefit verification.

The 5-year survival rate for people with mesothelioma, an asbestos-related cancer, is about 12% overall, with pleural mesothelioma at 12% and peritoneal mesothelioma at 65%. One-year survival is approximately 40% for pleural mesothelioma per SEER, with peritoneal mesothelioma (especially when treated with CRS plus HIPEC at high-volume centers) showing materially better outcomes. SEER rates vary by tumor location, stage, cell type, and treatment. Median survival after diagnosis averages 12 to 21 months for pleural mesothelioma.

Yes, available reports say Emily Whitehead remains cancer-free more than a decade after receiving CAR T-cell therapy. Sources from the Children’s Hospital of Philadelphia, the Cancer Research Institute, and the Emily Whitehead Foundation describe her as in long-term remission and, in some accounts, cured. Her case became a landmark in cancer treatment because it helped establish CAR T-cell therapy as a successful option for some people with blood cancers.